Giorgio Giaccone

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4695125/publications.pdf

Version: 2024-02-01

213	11,868	27035	36203
papers	citations	58	101
		h-index	g-index

221	221	221	12016
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	A modified Camel and Cactus Test detects presymptomatic semantic impairment in genetic frontotemporal dementia within the GENFI cohort. Applied Neuropsychology Adult, 2022, 29, 112-119.	0.7	18
2	Cognitive composites for genetic frontotemporal dementia: GENFI-Cog. Alzheimer's Research and Therapy, 2022, 14, 10.	3.0	4
3	MAPT Q336H mutation: Intrafamilial phenotypic heterogeneity in a new Italian family. European Journal of Neurology, 2022, , .	1.7	1
4	Validation of Revised International Creutzfeldt-Jakob Disease Surveillance Network Diagnostic Criteria for Sporadic Creutzfeldt-Jakob Disease. JAMA Network Open, 2022, 5, e2146319.	2.8	28
5	Examining empathy deficits across familial forms of frontotemporal dementia within the GENFI cohort. Cortex, 2022, 150, 12-28.	1.1	2
6	The novel I213S mutation in PSEN1 gene is located in a hotspot codon associated with familial early-onset Alzheimer's disease. Neurobiology of Aging, 2022, 112, 191-196.	1.5	1
7	Astrocytes expressing Vitamin Dâ€activating enzyme identify Parkinsonâ€™s disease. CNS Neuroscience and Therapeutics, 2022, 28, 703-713.	1.9	10
8	Structural brain splitting is a hallmark of Granulin-related frontotemporal dementia. Neurobiology of Aging, 2022, , .	1.5	1
9	PMCA-Based Detection of Prions in the Olfactory Mucosa of Patients With Sporadic Creutzfeldtâ€“Jakob Disease. Frontiers in Aging Neuroscience, 2022, 14, 848991.	1.7	4
10	The Alpha-Synuclein RT-QuIC Products Generated by the Olfactory Mucosa of Patients with Parkinsonâ€™s Disease and Multiple System Atrophy Induce Inflammatory Responses in SH-SY5Y Cells. Cells, 2022, 11, 87.	1.8	5
11	Serpin Signatures in Prion and Alzheimerâ€™s Diseases. Molecular Neurobiology, 2022, 59, 3778-3799.	1.9	18
12	P301L tau mutation leads to alterations of cell cycle, DNA damage response and apoptosis: Evidence for a role of tau in cancer. Biochemical Pharmacology, 2022, 200, 115043.	2.0	6
13	Neuropathological Alzheimerâ€™s Disease Lesions in Nasu-Hakola Disease with TREM2 Mutation: Atypical Distribution of Neurofibrillary Changes. Journal of Alzheimer's Disease, 2021, 79, 25-30.	1.2	4
14	Brain functional network integrity sustains cognitive function despite atrophy in presymptomatic genetic frontotemporal dementia. Alzheimer's and Dementia, 2021, 17, 500-514.	0.4	36
15	Cerebral amyloid angiopathy in a 51-year-old patient with embolization by dura mater extract and surgery for nasopharyngeal angiofibroma at age 17. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2021, 28, 142-143.	1.4	14
16	Singular cases of Alzheimerâ€™s disease disclose new and old genetic â€œacquaintancesâ€• Neurological Sciences, 2021, 42, 2021-2029.	0.9	4
17	Machine Learning Driven Profiling of Cerebrospinal Fluid Core Biomarkers in Alzheimerâ€™s Disease and Other Neurological Disorders. Frontiers in Neuroscience, 2021, 15, 647783.	1.4	17
18	Poly (ADP-ribose) polymerase 1 and Parkinson's disease: A study in post-mortem human brain. Neurochemistry International, 2021, 144, 104978.	1.9	8

#	Article	IF	Citations
19	Microglial Heterogeneity and Its Potential Role in Driving Phenotypic Diversity of Alzheimerâ€™s Disease. International Journal of Molecular Sciences, 2021, 22, 2780.	1.8	11
20	Early and long-term cognitive features in sporadic Creutzfeldt-Jakob disease. Neurological Sciences, 2021, 42, 3043-3045.	0.9	1
21	Gene Expression Imputation Across Multiple Tissue Types Provides Insight Into the Genetic Architecture of Frontotemporal Dementia and Its Clinical Subtypes. Biological Psychiatry, 2021, 89, 825-835.	0.7	10
22	PMCA-generated prions from the olfactory mucosa of patients with Fatal Familial Insomnia cause prion disease in mice. ELife, 2021, 10, .	2.8	4
23	Disease-related cortical thinning in presymptomatic granulin mutation carriers. NeuroImage: Clinical, 2021, 29, 102540.	1.4	8
24	Sporadic Creutzfeldt-Jakob disease: Real-Time Quaking Induced Conversion (RT-QuIC) assay represents a major diagnostic advance. European Journal of Histochemistry, 2021, 65, .	0.6	3
25	Discrimination of MSA-P and MSA-C by RT-QuIC analysis of olfactory mucosa: the first assessment of assay reproducibility between two specialized laboratories. Molecular Neurodegeneration, 2021, 16, 82.	4.4	28
26	An atypical presentation of diffuse midline pontine glioma in a middle age patient: Case report. Journal of Clinical Neuroscience, 2020, 71, 293-295.	0.8	0
27	One novel GRN null mutation, two different aphasia phenotypes. Neurobiology of Aging, 2020, 87, 141.e9-141.e14.	1.5	6
28	Cell-free amplification of prions: Where do we stand?. Progress in Molecular Biology and Translational Science, 2020, 175, 325-358.	0.9	7
29	The Rise of the GRN C157KfsX97 Mutation in Southern Italy: Going Back to the Fall of the Western Roman Empire. Journal of Alzheimer's Disease, 2020, 78, 387-394.	1.2	1
30	Mendelian randomization implies no direct causal association between leukocyte telomere length and amyotrophic lateral sclerosis. Scientific Reports, 2020, 10, 12184.	1.6	4
31	Understanding the Pathophysiology of Cerebral Amyloid Angiopathy. International Journal of Molecular Sciences, 2020, 21, 3435.	1.8	39
32	PMCA Applications for Prion Detection in Peripheral Tissues of Patients with Variant Creutzfeldt-Jakob Disease. Biomolecules, 2020, 10, 405.	1.8	14
33	Discovering the Italian phenotype of cerebral amyloid angiopathy (CAA): the SENECA project. Neurological Sciences, 2020, 41, 2193-2200.	0.9	3
34	Phospho-HDAC6 Gathers Into Protein Aggregates in Parkinsonâ€™s Disease and Atypical Parkinsonisms. Frontiers in Neuroscience, 2020, 14, 624.	1.4	17
35	Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 263-270.	0.9	106
36	Social cognition impairment in genetic frontotemporal dementia within the GENFI cohort. Cortex, 2020, 133, 384-398.	1.1	26

#	Article	IF	Citations
37	Synthetic Prion Selection and Adaptation. Molecular Neurobiology, 2019, 56, 2978-2989.	1.9	7
38	Efficient RT-QuIC seeding activity for Î±-synuclein in olfactory mucosa samples of patients with Parkinsonâ€™s disease and multiple system atrophy. Translational Neurodegeneration, 2019, 8, 24.	3.6	106
39	Genetic variation across RNA metabolism and cell death gene networks is implicated in the semantic variant of primary progressive aphasia. Scientific Reports, 2019, 9, 10854.	1.6	9
40	The inner fluctuations of the brain in presymptomatic Frontotemporal Dementia: The chronnectome fingerprint. NeuroImage, 2019, 189, 645-654.	2.1	33
41	Iatrogenic early onset cerebral amyloid angiopathy 30â€‰years after cerebral trauma with neurosurgery: vascular amyloid deposits are made up of both AÎ²40 and AÎ²42. Acta Neuropathologica Communications, 2019, 7, 70.	2.4	26
42	Prion Efficiently Replicates in Î±-Synuclein Knockout Mice. Molecular Neurobiology, 2019, 56, 7448-7457.	1.9	5
43	Early cortical and late striatal diffusion restriction on 3T MRI in a longâ€lived sporadic creutzfeldtâ€“jakob disease case. Journal of Magnetic Resonance Imaging, 2019, 50, 1659-1662.	1.9	1
44	White matter hyperintensities in progranulin-associated frontotemporal dementia: A longitudinal GENFI study. NeuroImage: Clinical, 2019, 24, 102077.	1.4	27
45	Dreaming of a New World Where Alzheimerâ€™s Is a Treatable Disorder. Frontiers in Aging Neuroscience, 2019, 11, 317.	1.7	14
46	Use of different RT-QuIC substrates for detecting CWD prions in the brain of Norwegian cervids. Scientific Reports, 2019, 9, 18595.	1.6	11
47	Clinical and neuropathological phenotype associated with the novel V189I mutation in the prion protein gene. Acta Neuropathologica Communications, 2019, 7, 1.	2.4	68
48	Functional network resilience to pathology in presymptomatic genetic frontotemporal dementia. Neurobiology of Aging, 2019, 77, 169-177.	1.5	47
49	Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia. Nature Medicine, 2019, 25, 152-164.	15.2	111
50	Effects of peptidyl-prolyl isomerase 1 depletion in animal models of prion diseases. Prion, 2018, 12, 127-137.	0.9	3
51	CXCR4 involvement in neurodegenerative diseases. Translational Psychiatry, 2018, 8, 73.	2.4	66
52	Molecular subtypes of Alzheimerâ€™s disease. Scientific Reports, 2018, 8, 3269.	1.6	68
53	In Situ Tissue Labeling of Cerebral Amyloid Using HIV-Related Tat Peptide. Molecular Neurobiology, 2018, 55, 6834-6840.	1.9	10
54	Frontotemporal Dementia and Chorea Associated with a Compound Heterozygous TREM2 Mutation. Journal of Alzheimer's Disease, 2018, 63, 195-201.	1.2	11

#	Article	IF	Citations
55	Translational Research in Alzheimerâ€™s and Prion Diseases. Journal of Alzheimer's Disease, 2018, 62, 1247-1259.	1.2	7
56	Alzheimer neuropathology without frontotemporal lobar degeneration hallmarks (<scp>TAR) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 707 T <scp>C</scp>ys139<scp>A</scp>rg. Brain Pathology, 2018, 28, 72-76.	2.1	16
57	An In Vivo 11C-(R)-PK11195 PET and In Vitro Pathology Study of Microglia Activation in Creutzfeldt-Jakob Disease. Molecular Neurobiology, 2018, 55, 2856-2868.	1.9	22
58	Neuro-BehÃ§etâ€™s disease presenting as an isolated progressive cognitive and behavioral syndrome. Neurocase, 2018, 24, 238-241.	0.2	2
59	A C6orf10/LOC101929163 locus is associated with age of onset in C9orf72 carriers. Brain, 2018, 141, 2895-2907.	3.7	39
60	Tau Mutations as a Novel Risk Factor for Cancerâ€”Response. Cancer Research, 2018, 78, 6525-6525.	0.4	18
61	Tau Mutations Serve as a Novel Risk Factor for Cancer. Cancer Research, 2018, 78, 3731-3739.	0.4	30
62	Sporadic Fatal Insomnia in Europe: Phenotypic Features and Diagnostic Challenges. Annals of Neurology, 2018, 84, 347-360.	2.8	31
63	Hemoglobin mRNA Changes in the Frontal Cortex of Patients with Neurodegenerative Diseases. Frontiers in Neuroscience, 2018, 12, 8.	1.4	26
64	Iatrogenic Creutzfeldt-Jakob disease with Amyloid-Î² pathology: an international study. Acta Neuropathologica Communications, 2018, 6, 5.	2.4	79
65	Immune-related genetic enrichment in frontotemporal dementia: An analysis of genome-wide association studies. PLoS Medicine, 2018, 15, e1002487.	3.9	111
66	Genetic architecture of sporadic frontotemporal dementia and overlap with Alzheimer's and Parkinson's diseases. Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 152-164.	0.9	107
67	Effects of Multiple Genetic Loci on Age atÂOnset in Frontotemporal Dementia. Journal of Alzheimer's Disease, 2017, 56, 1271-1278.	1.2	4
68	Multisite Assessment of Aging-Related Tau Astrogliopathy (ARTAG). Journal of Neuropathology and Experimental Neurology, 2017, 76, 605-619.	0.9	38
69	Missense mutation in GRN gene affecting RNA splicing and plasma progranulin level in a family affected by frontotemporal lobar degeneration. Neurobiology of Aging, 2017, 54, 214.e1-214.e6.	1.5	8
70	High diagnostic value of second generation CSF RT-QuIC across the wide spectrum of CJD prions. Scientific Reports, 2017, 7, 10655.	1.6	143
71	Susceptible genes and disease mechanisms identified in frontotemporal dementia and frontotemporal dementia with Amyotrophic Lateral Sclerosis by DNA-methylation and GWAS. Scientific Reports, 2017, 7, 8899.	1.6	30
72	Differential overexpression of SERPINA3 in human prion diseases. Scientific Reports, 2017, 7, 15637.	1.6	58

#	Article	IF	Citations
73	Towards an early clinical diagnosis of sporadic CJD VV2 (ataxic type). Journal of Neurology, Neurosurgery and Psychiatry, 2017, 88, 764-772.	0.9	33
74	Tackling amyloidogenesis in Alzheimerâ€™s disease with A2V variants of Amyloid-Î². Scientific Reports, 2016, 6, 20949.	1.6	26
75	Changes in brain oxysterols at different stages of Alzheimer's disease: Their involvement in neuroinflammation. Redox Biology, 2016, 10, 24-33.	3.9	192
76	A 52â€Yearâ€Old Man with Myoclonic Jerks. Brain Pathology, 2016, 26, 291-292.	2.1	2
77	Unusual presentations and intrafamilial phenotypic variability in infantile onset Alexander disease. Neurological Sciences, 2016, 37, 973-977.	0.9	7
78	Measles Inclusionâ€Body Encephalitis: Neuronal Phosphorylated Tau Protein is Present in the Biopsy but not in the Autoptic Specimens of the Same Patient. Brain Pathology, 2016, 26, 542-546.	2.1	2
79	Measles Inclusionâ€Body Encephalitis: Neuronal Phosphorylated Tau Protein is Present in the Biopsy but not in the Autoptic Specimens of the Same Patient. Brain Pathology, 2016, 26, 673-673.	2.1	1
80	Aging-related tau astrogliopathy (ARTAG): harmonized evaluation strategy. Acta Neuropathologica, 2016, 131, 87-102.	3.9	380
81	The Existence of Primary Age-Related Tauopathy Suggests that not all the Cases with Early Braak Stages of Neurofibrillary Pathology are Alzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 48, 919-921.	1.2	12
82	Mirror Image of the Amyloid-Î² Species in Cerebrospinal Fluid and Cerebral Amyloid inÂAlzheimerâ€™s Disease. Journal of Alzheimer's Disease, 2015, 47, 877-881.	1.2	9
83	Prodromal Alzheimer's Disease Presenting as Cerebral Amyloid Angiopathy-Related Inflammation with Spontaneous Amyloid-Related Imaging Abnormalities and High Cerebrospinal Fluid Anti-AÎ² Autoantibodies. Journal of Alzheimer's Disease, 2015, 45, 363-367.	1.2	36
84	Neuropathological assessments of the pathology in frontotemporal lobar degeneration with TDP43-positive inclusions: an inter-laboratory study by the BrainNet Europe consortium. Journal of Neural Transmission, 2015, 122, 957-972.	1.4	25
85	A genome-wide screening and SNPs-to-genes approach to identify novel genetic risk factors associated with frontotemporal dementia. Neurobiology of Aging, 2015, 36, 2904.e13-2904.e26.	1.5	48
86	Panencephalopathic Creutzfeldt-Jakob Disease with Distinct Pattern of Prion Protein Deposition in a Patient with D178N Mutation and Homozygosity for Valine at Codon 129 of the Prion Protein Gene. Brain Pathology, 2014, 24, 148-151.	2.1	7
87	Idiopathic progressive chorea: misnomer or still reality? A case with neuropathological disconfirmation. Neurological Sciences, 2014, 35, 1155-1156.	0.9	0
88	Doxycycline in Creutzfeldt-Jakob disease: a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Neurology, The, 2014, 13, 150-158.	4.9	157
89	Upâ€regulation of Î²â€amyloidogenesis in neuronâ€like human cells by both 24â€•and 27â€hydroxycholesterol: protective effect of Nâ€acetylâ€cysteine. Aging Cell, 2014, 13, 561-572.	3.0	52
90	Frontotemporal dementia and its subtypes: a genome-wide association study. Lancet Neurology, The, 2014, 13, 686-699.	4.9	302

#	Article	IF	Citations
91	Divergent Cognitive Status with the Same Braak Stage of Neurofibrillary Pathology: Does the Pattern of Amyloid-Î² Deposits Make the Difference?. Journal of Alzheimer's Disease, 2014, 43, 375-379.	1.2	4
92	Severe microcephaly with polynodular heterotopia: a highâ€field <scp>MRI</scp> and neuropathological case study. European Journal of Neurology, 2013, 20, e81-2.	1.7	0
93	Globular glial tauopathies (GGT): consensus recommendations. Acta Neuropathologica, 2013, 126, 537-544.	3.9	168
94	Neuropathology of the hippocampus in FTLDâ€Tau with Pick bodies: a study of the BrainNet Europe Consortium. Neuropathology and Applied Neurobiology, 2013, 39, 166-178.	1.8	54
95	Antiâ€“amyloid Î² autoantibodies in cerebral amyloid angiopathyâ€“related inflammation: Implications for amyloidâ€modifying therapies. Annals of Neurology, 2013, 73, 449-458.	2.8	179
96	Cathepsin F mutations cause Type B Kufs disease, an adult-onset neuronal ceroid lipofuscinosis. Human Molecular Genetics, 2013, 22, 1417-1423.	1.4	105
97	Hereditary and sporadic beta-amyloidoses. Frontiers in Bioscience - Landmark, 2013, 18, 1202.	3.0	9
98	A case of multiple sclerosis with pure, massive superficial demyelination. Neurology, 2012, 79, 384-386.	1.5	1
99	Brain delivery of AAV9 expressing an anti-PrP monovalent antibody delays prion disease in mice. Prion, 2012, 6, 383-390.	0.9	25
100	MM2â€Thalamic Creutzfeldtâ€“Jakob Disease: Neuropathological, Biochemical and Transmission Studies Identify a Distinctive Prion Strain. Brain Pathology, 2012, 22, 662-669.	2.1	62
101	Consensus classification of human prion disease histotypes allows reliable identification of molecular subtypes: an inter-rater study among surveillance centres in Europe and USA. Acta Neuropathologica, 2012, 124, 517-529.	3.9	184
102	APP mutations in the AÎ² coding region are associated with abundant cerebral deposition of AÎ²38. Acta Neuropathologica, 2012, 124, 809-821.	3.9	34
103	The need to unify neuropathological assessments of vascular alterations in the ageing brain. Experimental Gerontology, 2012, 47, 825-833.	1.2	57
104	New mutations in MAPT gene causing frontotemporal lobar degeneration: biochemical and structural characterization. Neurobiology of Aging, 2012, 33, 834.e1-834.e6.	1.5	28
105	Good gene, bad gene: New APP variant may be both. Progress in Neurobiology, 2012, 99, 281-292.	2.8	31
106	Lewy body pathology and typical Parkinson disease in a patient with a heterozygous (R275W) mutation in the Parkin gene (PARK2). Acta Neuropathologica, 2012, 123, 901-903.	3.9	22
107	Atypical tauopathy in a patient with LRRK2â€G2019S mutation and tremorâ€dominant Parkinsonism. Neuropathology and Applied Neurobiology, 2012, 38, 382-386.	1.8	23
108	A Novel Progranulin Mutation Causing Frontotemporal Lobar Degeneration with Heterogeneous Phenotypic Expression. Journal of Alzheimer's Disease, 2011, 23, 7-12.	1.2	18

#	Article	IF	Citations
109	A Novel Pathogenic PSEN1 Mutation in a Family with Alzheimer's Disease: Phenotypical and Neuropathological Features. Journal of Alzheimer's Disease, 2011, 25, 425-431.	1.2	14
110	Variability of the Clinical Phenotype in an Italian Family with Dementia Associated with an Intronic Deletion in the GRN Gene. Journal of Alzheimer's Disease, 2011, 26, 583-590.	1.2	11
111	New lexicon and criteria for the diagnosis of Alzheimer's disease. Lancet Neurology, The, 2011, 10, 298-299.	4.9	26
112	Neuropathology of the recessive A673V APP mutation: Alzheimer disease with distinctive features. Acta Neuropathologica, 2010, 120, 803-812.	3.9	61
113	Variably proteaseâ€sensitive prionopathy: A new sporadic disease of the prion protein. Annals of Neurology, 2010, 68, 162-172.	2.8	203
114	Myoclonus in Creutzfeldtâ€Jakob disease: Polygraphic and videoâ€electroencephalography assessment of 109 patients. Movement Disorders, 2010, 25, 2818-2827.	2.2	27
115	Neocortical Variation of AÎ² Load in Fully Expressed, Pure Alzheimer's Disease. Journal of Alzheimer's Disease, 2010, 19, 57-68.	1.2	19
116	Worldwide distribution of PSEN1 Met146Leu mutation. Neurology, 2010, 74, 798-806.	1.5	38
117	Hereditary Cerebral Hemorrhage With Amyloidosis Associated With the E693K Mutation of APP. Archives of Neurology, 2010, 67, 987-95.	4.9	87
118	A Novel Italian Presenilin 2 Gene Mutation with Prevalent Behavioral Phenotype. Journal of Alzheimer's Disease, 2009, 16, 509-511.	1.2	39
119	An atypical case of sporadic fatal insomnia. Journal of Neurology, Neurosurgery and Psychiatry, 2009, 80, 924-927.	0.9	6
120	Joubert syndrome with bilateral polymicrogyria: Clinical and neuropathological findings in two brothers. American Journal of Medical Genetics, Part A, 2009, 149A, 1511-1515.	0.7	22
121	Assessment of Î²-amyloid deposits in human brain: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 309-320.	3.9	143
122	Staging/typing of Lewy body related Î±-synuclein pathology: a study of the BrainNet Europe Consortium. Acta Neuropathologica, 2009, 117, 635-652.	3.9	249
123	Reviews: Current Concepts in Alzheimer's Disease: A Multidisciplinary Review. American Journal of Alzheimer's Disease and Other Dementias, 2009, 24, 95-121.	0.9	245
124	The behavioural features of fatal familial insomnia: A new Italian case with pathological verification. Sleep Medicine, 2009, 10, 581-585.	0.8	10
125	APE1/Ref-1 in Alzheimer's disease: An immunohistochemical study. Neuroscience Letters, 2009, 466, 124-127.	1.0	34
126	A novel phenotype of sporadic Creutzfeldt-Jakob disease. BMJ Case Reports, 2009, 2009, bcr0920080945-bcr0920080945.	0.2	0

#	Article	IF	Citations
127	Inter-laboratory comparison of neuropathological assessments of Î²-amyloid protein: a study of the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 533-546.	3.9	86
128	Management of a twenty-first century brain bank: experience in the BrainNet Europe consortium. Acta Neuropathologica, 2008, 115, 497-507.	3.9	101
129	Staging of Neurofibrillary Pathology in Alzheimer's Disease: A Study of the BrainNet Europe Consortium. Brain Pathology, 2008, 18, 484-496.	2.1	361
130	Atypical tauopathy with massive involvement of the white matter. Neuropathology and Applied Neurobiology, 2008, 34, 468-472.	1.8	23
131	Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Neurobiology of Aging, 2008, 29, 1864-1873.	1.5	51
132	A new function of microtubule-associated protein tau: Involvement in chromosome stability. Cell Cycle, 2008, 7, 1788-1794.	1.3	89
133	A novel PSEN2 mutation associated with a peculiar phenotype. Neurology, 2008, 70, 1549-1554.	1.5	62
134	Late presentation of leucoencephalopathy with calcifications and cysts: report of two cases. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1303-1304.	0.9	21
135	A novel insertional mutation in the prion protein gene: clinical and bio-molecular findings. Journal of Neurology, Neurosurgery and Psychiatry, 2008, 79, 1395-1398.	0.9	16
136	Assessment of Î±-Synuclein Pathology: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2008, 67, 125-143.	0.9	73
137	Conversion of the BASE Prion Strain into the BSE Strain: The Origin of BSE?. PLoS Pathogens, 2007, 3, e31.	2.1	146
138	A novel phenotype of sporadic Creutzfeldt Jakob disease. Journal of Neurology, Neurosurgery and Psychiatry, 2007, 78, 1379-1382.	0.9	15
139	The Îµ Isoform of 14-3-3 Protein Is a Component of the Prion Protein Amyloid Deposits of Gerstmann-StrÃussler-Scheinker Disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 124-130.	0.9	15
140	Brain Protein Preservation Largely Depends on the Postmortem Storage Temperature. Journal of Neuropathology and Experimental Neurology, 2007, 66, 35-46.	0.9	151
141	Effects of Formalin Fixation, Paraffin Embedding, and Time of Storage on DNA Preservation in Brain Tissue: A BrainNet Europe Study. Brain Pathology, 2007, 17, 297-303.	2.1	127
142	How a neuropsychiatric brain bank should be run: a consensus paper of Brainnet Europe II. Journal of Neural Transmission, 2007, 114, 527-537.	1.4	49
143	Spinocerebellar ataxia type 17 (SCA17): Oculomotor phenotype and clinical characterization of 15 Italian patients. Journal of Neurology, 2007, 254, 1538-1546.	1.8	78
144	Tauopathy in human and experimental variant Creutzfeldt-Jakob disease. Journal of Neuropathology and Experimental Neurology, 2007, 66, 430.	0.9	0

#	Article	IF	Citations
145	Interlaboratory Comparison of Assessments of Alzheimer Disease-Related Lesions: A Study of the BrainNet Europe Consortium. Journal of Neuropathology and Experimental Neurology, 2006, 65, 740-757.	0.9	95
146	Pathologic prion protein is specifically recognized in situ by a novel PrP conformational antibody. Neurobiology of Disease, 2006, 23, 717-724.	2.1	22
147	Periodic electroencephalogram complexes in a patient with variant Creutzfeldtâ€“Jakob disease. Annals of Neurology, 2006, 59, 423-427.	2.8	39
148	Cognitive Deficits in Familial Alzheimerâ€™s Disease Associated with M239V Mutation of Presenilin 2. Dementia and Geriatric Cognitive Disorders, 2006, 22, 238-243.	0.7	11
149	Sporadic Creutzfeldt-Jakob Disease: The Extent of Microglia Activation Is Dependent on the Biochemical Type of PrPSc. Journal of Neuropathology and Experimental Neurology, 2005, 64, 902-909.	0.9	33
150	Familial frontotemporal dementia associated with the novel MAPT mutation T427M. Journal of Neurology, 2005, 252, 1543-1545.	1.8	13
151	Role of Plasminogen in Propagation of Scrapie. Journal of Virology, 2005, 79, 11225-11230.	1.5	18
152	Defective Tumor Necrosis Factor-Î±-dependent Control of Astrocyte Glutamate Release in a Transgenic Mouse Model of Alzheimer Disease. Journal of Biological Chemistry, 2005, 280, 42088-42096.	1.6	48
153	FVEPs in Creutzfeldtâ€“Jacob disease: waveforms and interaction with the periodic EEG pattern assessed by single sweep analysis. Clinical Neurophysiology, 2005, 116, 895-904.	0.7	4
154	Neuropathological and Clinical Phenotype of an Italian Alzheimer Family with M239V Mutation of Presenilin 2 Gene. Journal of Neuropathology and Experimental Neurology, 2004, 63, 199-209.	0.9	39
155	Prion deposition in olfactory biopsy of sporadic Creutzfeldt-Jakob disease. Annals of Neurology, 2004, 55, 294-296.	2.8	57
156	P3-332 Familial frontotemporal dementia associated with the novel tau mutation T427M. Neurobiology of Aging, 2004, 25, S449-S450.	1.5	1
157	P3-382 Insertional mutation in the prion protein gene presenting with Schizophrenia. Neurobiology of Aging, 2004, 25, S464.	1.5	1
158	A family with Alzheimer disease and strokes associated with A713T mutation of the APP gene. Neurology, 2004, 63, 910-912.	1.5	66
159	Creutzfeldt-Jakob disease with a novel extra-repeat insertional mutation in the PRNP gene. Neurology, 2003, 61, 1288-1291.	1.5	31
160	Tetracyclines affect prion infectivity. Proceedings of the National Academy of Sciences of the United States of America, 2002, 99, 10849-10854.	3.3	184
161	Anti-amyloidogenic effect of tetracyclines in Prion and Alzheimer disease models. European Neuropsychopharmacology, 2002, 12, 91.	0.3	1
162	Ectopic White Matter Neurons, a Developmental Abnormality That May Be Caused by thePSEN1S169L Mutation in a Case of Familial AD with Myoclonus and Seizures. Journal of Neuropathology and Experimental Neurology, 2001, 60, 1137-1152.	0.9	47

#	Article	IF	Citations
163	A 7-kDa Prion Protein (PrP) Fragment, an Integral Component of the PrP Region Required for Infectivity, Is the Major Amyloid Protein in Gerstmann-StrÃussler-Scheinker Disease A117V. Journal of Biological Chemistry, 2001, 276, 6009-6015.	1.6	119
164	Neuropathology of Gerstmann-Strï¿½ussler-Scheinker disease. Microscopy Research and Technique, 2000, 50, 10-15.	1.2	53
165	Polymorphism at codon 129 ofPRNP affects the phenotypic expression of Creutzfeldt-Jakob disease linked to E200K mutation. Annals of Neurology, 2000, 48, 269-270.	2.8	30
166	Creutzfeldtâ€“Jakob disease with a novel four extra-repeat insertional mutation in the PrP gene. Neurology, 2000, 55, 405-410.	1.5	49
167	Substitutions at codon 22 of Alzheimer's A beta peptide induce conformational changes and diverse apoptotic effects in human cerebral endothelial cells. Journal of Biological Chemistry, 2000, 275, 27110-6.	1.6	119
168	Creutzfeldtâ€Jakob Disease: Carnoy's Fixative Improves the Immunohistochemistry of the Proteinase Kâ€• Resistant Prion Protein. Brain Pathology, 2000, 10, 31-37.	2.1	49
169	Sporadic Creutzfeldt-Jakob disease: Co-occurrence of different types of PrP ^{Sc} in the same brain. Neurology, 1999, 53, 2173-2173.	1.5	185
170	Development of layer I of the human cerebral cortex after midgestation: Architectonic findings, immunocytochemical identification of neurons and glia, and in situ labeling of apoptotic cells. Journal of Comparative Neurology, 1999, 410, 126-142.	0.9	45
171	A Î²PP Peptide Carboxyl-Terminal to AÎ² Is Neurotoxic. American Journal of Pathology, 1999, 154, 1001-1007.	1.9	18
172	NEUROPATHOLOGICAL CORRELATES OF MAGNETIC RESONANCE ABNORMALITIES IN EXPERIMENTAL PRION DISEASE. Journal of Neuropathology and Experimental Neurology, 1999, 58, 560.	0.9	5
173	Frontotemporal Dementia and Corticobasal Degeneration in a Family with a P301S Mutation in Tau. Journal of Neuropathology and Experimental Neurology, 1999, 58, 667-677.	0.9	381
174	Fatal familial insomnia. Neurology, 1998, 50, 688-692.	1.5	50
175	PRION PROTEIN IMMUNOHISTOCHEMISTRY IN CREUTZFELDT-JAKOB DISEASE. Journal of Neuropathology and Experimental Neurology, 1998, 57, 493.	0.9	0
176	PrP Peptides as a Tool to Investigate the Pathogenesis of Prion Protein Amyloidoses. , 1998, , 285-289.		0
177	ANTHRACYCLINES EFFECTIVE AGAINST EXPERIMENTAL SCRAPIE. Journal of Neuropathology and Experimental Neurology, 1997, 56, 595.	0.9	0
178	Effectiveness of Anthracycline Against Experimental Prion Disease in Syrian Hamsters. Science, 1997, 276, 1119-1121.	6.0	168
179	A Neurotoxic and Gliotrophic Fragment of the Prion Protein Increases Plasma Membrane Microviscosity. Neurobiology of Disease, 1997, 4, 47-57.	2.1	60
180	Diffuse thalamic degeneration in fatal familial insomnia. A morphometric study. Brain Research, 1997, 771, 154-158.	1.1	34

#	Article	IF	Citations
181	Prion protein hereditary amyloidosis: parenchymal and vascular. Seminars in Virology, 1996, 7, 189-200.	4.1	11
182	Vascular variant of prion protein cerebral amyloidosis with tau-positive neurofibrillary tangles: the phenotype of the stop codon 145 mutation in PRNP.. Proceedings of the National Academy of Sciences of the United States of America, 1996, 93, 744-748.	3.3	270
183	TOPOGRAPHY OF PHOSPHORYLATED TAU IMMUNOREACTIVITY IN ALZHEIMER DISEASE, PROGRESSIVE SUPRANUCLEAR PALSY AND PICK DISEASE. Journal of Neuropathology and Experimental Neurology, 1996, 55, 634.	0.9	0
184	Prion Protein Amyloidosis. Brain Pathology, 1996, 6, 127-145.	2.1	185
185	ONLY MUTANT PRP PARTICIPATES IN AMYLOID FORMATION IN GERSTMANN-STRÃ„USSLER-SCHEINKER DISEASE WITH ALA>VAL SUBSTITUTION AT CODON 117. Journal of Neuropathology and Experimental Neurology, 1995, 54, 416.	0.9	10
186	Gerstmann-StrÃussler-Scheinker Disease (PRNP P102L): Amyloid Deposits Are Best Recognized by Antibodies Directed to Epitopes in PrP Region 90-165. Journal of Neuropathology and Experimental Neurology, 1995, 54, 790-801.	0.9	36
187	Tau protein directly interacts with the amyloid Î²-protein precursor: Implications for Alzheimer's disease. Nature Medicine, 1995, 1, 365-369.	15.2	81
188	Gerstmannâ€šStrÃusslerâ€šScheinker Disease and the Indiana Kindred. Brain Pathology, 1995, 5, 61-75.	2.1	145
189	Familial Gerstmann-StrÃussler-Scheinker disease with neurofibrillary tangles. Molecular Neurobiology, 1994, 8, 41-48.	1.9	71
190	A Neurotoxic Prion Protein Fragment Induces Rat Astroglial Proliferation and Hypertrophy. European Journal of Neuroscience, 1994, 6, 1415-1422.	1.2	112
191	Amyloid fibrils in Gerstmann-StrÃussler-Scheinker disease (Indiana and Swedish Kindreds) express only PrP peptides encoded by the mutant allele. Cell, 1994, 79, 695-703.	13.5	152
192	Apolipoprotein E and J immunoreactivity in Gerstmann-StrÃussler-Scheinker disease. Neurobiology of Aging, 1994, 15, S156-S157.	1.5	12
193	Cerebrospinal fluid levels of amyloid Î²â€protein precursor are low in Gerstmannâ€šStralˆusslerâ€šScheinker disease, Indiana kindred. Neurology, 1994, 44, 1508-1508.	1.5	2
194	Ubiquitinated neurites are associated with preamyloid and cerebral amyloid ? deposits in patients with hereditary cerebral hemorrhage with amyloidosis Dutch type. Acta Neuropathologica, 1993, 85, 267-71.	3.9	16
195	A68 is a component of paired helical filaments of Gerstmann-StrÃussler-Scheinker disease, Indiana kindred. Brain Research, 1993, 616, 325-329.	1.1	54
196	Synthetic peptides homologous to prion protein residues 106-147 form amyloid-like fibrils in vitro.. Proceedings of the National Academy of Sciences of the United States of America, 1993, 90, 9678-9682.	3.3	242
197	ÃŸPP Participates in PrP-Amyloid Plaques of Gerstmann-StrÃussler-Scheinker Disease, Indiana Kindred. Journal of Neuropathology and Experimental Neurology, 1993, 52, 64-70.	0.9	49
198	EXPERIMENTAL (HAMSTER) SCRAPIE. Journal of Neuropathology and Experimental Neurology, 1993, 52, 294.	0.9	2

#	Article	IF	Citations
199	Prion protein preamyloid and amyloid deposits in Gerstmann-Straussler-Scheinker disease, Indiana kindred.. Proceedings of the National Academy of Sciences of the United States of America, 1992, 89, 9349-9353.	3.3	84
200	Alzheimer patients: Preamyloid deposits are immunoreactive with antibodies to extracellular domains of the amyloid precursor protein. Neuroscience Letters, 1991, 128, 117-120.	1.0	16
201	Relationship between non-fibrillary amyloid precursors and cell processes in the cortical neuropil of Alzheimer patients. Neuroscience Letters, 1991, 129, 119-122.	1.0	18
202	Preamyloid Deposits, Amyloid Deposits, and Senile Plaques in Alzheimer's Disease, Down Syndrome, and Aging. Annals of the New York Academy of Sciences, 1991, 640, 122-128.	1.8	14
203	Alzheimer patients and Down patients: Abnormal presynaptic terminals are related to cerebral preamyloid deposits. Neuroscience Letters, 1990, 119, 56-59.	1.0	55
204	Cerebral preamyloid deposits and congophilic angiopathy in aged dogs. Neuroscience Letters, 1990, 114, 178-183.	1.0	89
205	Neurofibrillary tangles of the Indiana kindred of Gerstmann-StraÂ¨ussler-Scheinker disease share antigenic determinants with those of Alzheimer disease. Brain Research, 1990, 530, 325-329.	1.1	71
206	Alzheimer patients: preamyloid deposits are more widely distributed than senile plaques throughout the central nervous system. Neuroscience Letters, 1989, 103, 263-268.	1.0	58
207	Alzheimer patients and Down patients: Cerebral preamyloid deposits differ ultrastructurally and histochemically from the amyloid of senile plaques. Neuroscience Letters, 1989, 105, 294-299.	1.0	87
208	Down patients: Extracellular preamyloid deposits precede neuritic degeneration and senile plaques. Neuroscience Letters, 1989, 97, 232-238.	1.0	242
209	Gerstmannâ€Straìˆusslerâ€Scheinker disease II. Neurofibrillary tangles and plaques with PrPâ€amyloid coexist in an affected family. Neurology, 1989, 39, 1453-1453.	1.5	161
210	Progressive supranuclear palsy with hypertrophy of the olives. Acta Neuropathologica, 1988, 77, 14-20.	3.9	22
211	Preamyloid deposits in the cerebral cortex of patients with Alzheimer's disease and nondemented individuals. Neuroscience Letters, 1988, 93, 191-196.	1.0	274
212	Glial fibrillary acidic protein and vimentin in the experimental glial reaction of the rat brain. Brain Research, 1986, 374, 110-118.	1.1	226
213	Immunohistochemical demonstration of vimentin in human cerebral tumors. Acta Neuropathologica, 1986, 70, 209-219.	3.9	71